PentixaPharm is proceeding its development pipeline in lymphoma located in the central nervous system in an advanced diagnostic trial with the PET-based agent PentixaFor as well as an early phase therapeutic trial with the targeted radiotherapy agent PentixaTher.

PentixaFor, a small peptide based [68Ga]Gallium PET imaging agent, addresses specifically the chemokine 4 receptor, expressed by a multitude of malignant diseases in oncological, cardiovascular and  inflammatory indications allowing for personalised molecular imaging with high specificity and sensitivity. 

PentixaTher, the complementary therapeutic agent to PentixaFor, equipped with the high energy beta emitter [90Y]Yttrium targets oncological malignancies via internal peptide receptor radioligand therapy. 

The lead development for PentixaFor and PentixaTher focuses on hematological indications targeting unmet medical needs for patients and offers benefits over existing therapies via a reduced side effect profile. 


PentixaPharm GmbH

Bismarckstraße 13
97080 Würzburg
Fon +49 931 991360-76

Robert-Rössle-Str. 10
13125 Berlin
Fon +49 30 9489-3220

Mail info@pentixapharm.com